vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.3× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 4.4%, a 12.5% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 10.1%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $345.8M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
JAZZ vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.5B |
| Net Profit | $203.5M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 21.2% | 12.4% |
| Net Margin | 17.0% | 4.4% |
| Revenue YoY | 10.1% | 32.8% |
| Net Profit YoY | 6.5% | 143.8% |
| EPS (diluted) | $3.34 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $897.8M | $1.1B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.0B | $929.2M | ||
| Q1 24 | $902.0M | $751.7M |
| Q4 25 | $203.5M | $66.5M | ||
| Q3 25 | $251.4M | $124.8M | ||
| Q2 25 | $-718.5M | $94.3M | ||
| Q1 25 | $-92.5M | $1.3M | ||
| Q4 24 | $191.1M | $-151.9M | ||
| Q3 24 | $215.1M | $-121.3M | ||
| Q2 24 | $168.6M | $-120.4M | ||
| Q1 24 | $-14.6M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | 21.2% | 12.4% | ||
| Q3 25 | 5.1% | 11.5% | ||
| Q2 25 | -65.6% | 6.7% | ||
| Q1 25 | -6.2% | 1.0% | ||
| Q4 24 | 17.5% | -7.0% | ||
| Q3 24 | 24.7% | -12.0% | ||
| Q2 24 | 19.5% | -11.5% | ||
| Q1 24 | 7.3% | -34.8% |
| Q4 25 | 17.0% | 4.4% | ||
| Q3 25 | 22.3% | 8.8% | ||
| Q2 25 | -68.7% | 7.2% | ||
| Q1 25 | -10.3% | 0.1% | ||
| Q4 24 | 17.6% | -13.5% | ||
| Q3 24 | 20.4% | -12.1% | ||
| Q2 24 | 16.5% | -13.0% | ||
| Q1 24 | -1.6% | -33.4% |
| Q4 25 | $3.34 | $0.05 | ||
| Q3 25 | $4.08 | $0.08 | ||
| Q2 25 | $-11.74 | $0.06 | ||
| Q1 25 | $-1.52 | $0.00 | ||
| Q4 24 | $2.97 | $-0.10 | ||
| Q3 24 | $3.42 | $-0.09 | ||
| Q2 24 | $2.49 | $-0.09 | ||
| Q1 24 | $-0.23 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $4.5B |
| Total DebtLower is stronger | $5.4B | $836.4M |
| Stockholders' EquityBook value | $4.3B | $4.4B |
| Total Assets | $11.7B | $8.2B |
| Debt / EquityLower = less leverage | 1.24× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $4.5B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $1.2B | $2.8B | ||
| Q1 25 | $1.9B | $2.5B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $2.2B | $2.7B | ||
| Q2 24 | $1.4B | $2.6B | ||
| Q1 24 | $1.4B | $2.8B |
| Q4 25 | $5.4B | $836.4M | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $4.4B | ||
| Q3 25 | $4.0B | $4.1B | ||
| Q2 25 | $3.7B | $3.8B | ||
| Q1 25 | $4.2B | $3.5B | ||
| Q4 24 | $4.1B | $3.3B | ||
| Q3 24 | $4.2B | $3.4B | ||
| Q2 24 | $3.8B | $3.4B | ||
| Q1 24 | $3.7B | $3.4B |
| Q4 25 | $11.7B | $8.2B | ||
| Q3 25 | $11.4B | $7.6B | ||
| Q2 25 | $10.9B | $6.3B | ||
| Q1 25 | $11.5B | $5.8B | ||
| Q4 24 | $12.0B | $5.9B | ||
| Q3 24 | $12.3B | $5.8B | ||
| Q2 24 | $11.4B | $5.7B | ||
| Q1 24 | $11.3B | $5.7B |
| Q4 25 | 1.24× | 0.19× | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $417.3M |
| Free Cash FlowOCF − Capex | $345.8M | $379.8M |
| FCF MarginFCF / Revenue | 28.9% | 25.4% |
| Capex IntensityCapex / Revenue | 1.4% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.78× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $417.3M | ||
| Q3 25 | $474.6M | $402.6M | ||
| Q2 25 | $88.9M | $263.6M | ||
| Q1 25 | $429.8M | $44.1M | ||
| Q4 24 | $398.6M | $75.2M | ||
| Q3 24 | $398.7M | $188.4M | ||
| Q2 24 | $331.4M | $-95.6M | ||
| Q1 24 | $267.2M | $-308.6M |
| Q4 25 | $345.8M | $379.8M | ||
| Q3 25 | $459.4M | $354.5M | ||
| Q2 25 | $75.9M | $219.8M | ||
| Q1 25 | $415.9M | $-12.3M | ||
| Q4 24 | $385.3M | $-17.3M | ||
| Q3 24 | $388.0M | $54.7M | ||
| Q2 24 | $324.3M | $-205.5M | ||
| Q1 24 | $260.3M | $-465.1M |
| Q4 25 | 28.9% | 25.4% | ||
| Q3 25 | 40.8% | 25.1% | ||
| Q2 25 | 7.3% | 16.7% | ||
| Q1 25 | 46.3% | -1.1% | ||
| Q4 24 | 35.4% | -1.5% | ||
| Q3 24 | 36.8% | 5.5% | ||
| Q2 24 | 31.7% | -22.1% | ||
| Q1 24 | 28.9% | -61.9% |
| Q4 25 | 1.4% | 2.5% | ||
| Q3 25 | 1.3% | 3.4% | ||
| Q2 25 | 1.2% | 3.3% | ||
| Q1 25 | 1.5% | 5.0% | ||
| Q4 24 | 1.2% | 8.2% | ||
| Q3 24 | 1.0% | 13.3% | ||
| Q2 24 | 0.7% | 11.8% | ||
| Q1 24 | 0.8% | 20.8% |
| Q4 25 | 1.78× | 6.28× | ||
| Q3 25 | 1.89× | 3.22× | ||
| Q2 25 | — | 2.79× | ||
| Q1 25 | — | 34.71× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
ONC
Segment breakdown not available.
